Cipralex vs. placebo

Adjusted mean change from baseline in LSAS total score (ref.1)

Adjusted mean difference from baseline in LSAS total score by visit (FAS, OC). Difference versus placebo.
  • In SAD, Cipralex showed superior efficacy over placebo on the Liebowitz Social Anxiety Scale (LSAS).

SDS subscale score at endpoint (ref.2)

Time to relapse (increse in LSAS total score of ≥10 points from randomisation, or withdrawal due to lack of efficacy).
** p<0.001 vs. placebo
  • Clinical relevance of Cipralex compared with placebo was indicated by the improvement of work and social-life items of the Sheehan disability scale.

Reference:

1. Lader et al., 2004

2. Adaped from Montgomery et al. J Clin Psychiatry 2005;66:1270-8

Published: 03/05/2006   Last updated: 27/07/2010
 
Key publications

www.irecover.com www.mypdinfo.com www.ebixa.com www.azilect.com www.serdolect.com www.depnet.com Disclaimer

H. Lundbeck A/S - Ottiliavej 9 - DK-2500 Copenhagen Valby - Phone +45 3630 1311 - Contact us

Lundbeck logo